Clinical Trial Update: Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-Risk Patients With the Use of the Dye-Vert Plus System [Phase 4]

View source ↗

Summary

A phase 4 clinical trial evaluating the Dye-Vert Plus System to reduce contrast-induced nephropathy in high-risk patients; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury Due to Trauma

Drugs mentioned

• Dye-Vert Plus System

Snippet

Sponsor: CAMC Health System | Conditions: AKI (Acute Kidney Injury) Due to Trauma | Phase 4 | Status: RECRUITING